Fintel reports that on January 6, 2026, Citigroup upgraded their outlook for Arvinas (NasdaqGS:ARVN) from Neutral to Buy.

Investors are always looking for stocks that are poised to beat at earnings season and Arvinas, Inc. ARVN may be one such company. The firm has earnings coming up pretty soon, and events are shaping ...

Arvinas, Inc. (ARVN) shares soared 8.8% in the last trading session to close at $9.03. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

As of November 27, 2023, the average one-year price target for Arvinas is 55.14. The forecasts range from a low of 20.20 to a high of $99.75. The average price target represents an increase of 137.98% ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Arvinas, Inc. (ARVN) is a stock that can certainly grab the ...

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a ...

Arvinas (ARVN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ...

The U.S. had a Christmas gift for each of the men in South Viet Nam’s 1st Regiment of the 1st Division, based just south of the Demilitarized Zone. It was the lightweight, fast-firing M-16 rifle, ...

The stock price of Arvinas (NASDAQ: ARVN), a biopharmaceuticals company focused on oncology treatments based on targeted protein degradation, reached an all-time high of $108 in July of this year ...

Though the battle headlines—and of late the casualty figures—emphasize the role of U.S. fighting men in Viet Nam, the largest body of troops on either side of the war is still the Army of the Republic ...